ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,578Medicare Part D Prescriptions Filled, Including Refills

Rank: 301 out of 972

$446K Total Retail Price of All Prescriptions

Rank: 378 out of 972

668 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
9% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Missouri
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 668 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

7% of this provider’s 668 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 9,123 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Missouri
LOVASTATIN 643 619 1 22
AMLODIPINE BESYLATE 628 602 2 4
ENALAPRIL MALEATE 402 391 3 50
FENOFIBRATE 252 250 4 66
OMEPRAZOLE 225 215 5 5
METFORMIN HCL 219 205 6 8
HYDROCHLOROTHIAZIDE 217 201 7 10
ATORVASTATIN CALCIUM 212 204 8 11
WARFARIN SODIUM 207 207 9 12
LEVOTHYROXINE SODIUM 204 194 10 3
LISINOPRIL 203 192 11 1
METOPROLOL TARTRATE 199 187 12 9
SERTRALINE HCL 186 172 13 25
FUROSEMIDE 161 159 14 7
ATENOLOL 157 152 15 18
HYDROCODONE-ACETAMINOPHEN 141 129 S3 16 6
LOSARTAN POTASSIUM 120 103 17 17
SIMVASTATIN 119 109 18 2
CLONIDINE HCL 118 118 19 57
GLIPIZIDE 107 104 20 59
METOPROLOL SUCCINATE 95 95 21 16
TRAZODONE HCL 95 80 21 35
TAMSULOSIN HCL 93 92 23 29
MELOXICAM 92 86 24 36
POTASSIUM CHLORIDE 90 90 25 13
DOXAZOSIN MESYLATE 86 77 26 82
TRIAMTERENE-HCTZ 75 75 27 39
NEXIUM 74 63 28 30
PANTOPRAZOLE SODIUM 72 53 29 41
DONEPEZIL HCL 71 71 30 26
PAROXETINE HCL 71 71 30 64
ALLOPURINOL 71 71 30 28
ALENDRONATE SODIUM 71 71 30 27
CLOPIDOGREL 70 70 34 37
PLAVIX 66 66 35 55
GABAPENTIN 66 64 35 14
FLUTICASONE PROPIONATE 65 63 37 31
TRAMADOL HCL 63 59 38 15
AZITHROMYCIN 61 54 39 42
PREDNISONE 58 56 40 40
LOSARTAN-HYDROCHLOROTHIAZIDE 57 56 41 61
DETROL LA 53 53 42 170
NIASPAN 51 51 43 144
CAPTOPRIL 51 51 43 256
DIGOXIN 51 51 43 52
ZETIA 50 50 46 79
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 21, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.